Gabriela Gruia Buys Shares of Aprea Therapeutics, Inc. (APRE)

Gabriela Gruia, an insider at Aprea Therapeutics, Inc. (NasdaqCM: APRE), purchased 12,555 shares of the company on June 16, 2026. The transaction did not involve a planned purchase under Rule 10b5-1.

Other Institutional Activity in Aprea Therapeutics

AIGH Capital Management LLC significantly increased its holdings in Aprea Therapeutics by adding 645,000 shares, bringing its total to 1,015,541 shares, valued at approximately $774,757. Vestal Point Capital, LP also entered the scene with 350,000 shares worth about $267,015. Geode Capital Management, LLC boosted its position by 78,181 shares, ending with 119,131 shares valued at around $90,890. Meanwhile, Sphera Funds Management Ltd. and Nantahala Capital Management, LLC maintained their positions with 270,000 and 205,760 shares, respectively.

Aprea Therapeutics, Inc. Stock Down 7.0%

Shares of Aprea Therapeutics, Inc. (NasdaqCM: APRE) traded near $0.73. The company has a market cap of approximately $9.66 million and a beta of 1.558, which suggests higher volatility compared to the overall market. Its 52-week range spans from a low of $0.55 to a high of $2.22. The stock's 50-day moving average is $0.85, and the 200-day moving average is $1.02. Aprea has a strong liquidity position with a current ratio of 8.92 and a quick ratio of 8.773.

Recent Earnings

Aprea Therapeutics reported revenue of $123,296, though it is not currently profitable. The company's return on equity stands at -40.4%, reflecting challenges in generating positive returns. The next earnings announcement is expected on August 11, 2025.

Insider Buying and Selling at Aprea Therapeutics, Inc.

On June 16, 2026, several insiders purchased shares of Aprea Therapeutics. Bernd Seizinger, Rifat Pamukcu, and Marc Duey each acquired 12,555 shares, while Jean-Pierre Bizzari and Michael Grissinger bought 3,135 shares each. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On May 14, 2026, Wedbush maintained its 'buy' rating for Aprea Therapeutics with a price target of $6.00. Oppenheimer initiated coverage with a 'buy' rating and a $5.00 target on May 7, 2026. HC Wainwright & Co. has consistently maintained a 'buy' rating with targets ranging from $1.20 to $20.00. Analysts collectively recommend the stock as a 'strong buy', with an average target price of $4.30 based on four opinions.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The company specializes in synthetic lethality-based therapeutics that target DNA damage response pathways. Aprea's lead products include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in early clinical trials. Headquartered in Doylestown, Pennsylvania, the company is led by CEO Dr. Oren Gilad.

Bottom Line

Gabriela Gruia’s recent purchase of Aprea Therapeutics shares signals insider confidence in the company. As a clinical-stage player in the biotechnology sector, Aprea is closely watched for its innovative cancer therapies. Analysts' strong buy ratings reflect optimism about the company's potential. Investors should remember that insider transactions are disclosed after they occur and may not reflect current positions.